Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells
=======================================================================================================================

* Kathryn M LaPorte
* Rosmely Hernandez
* Alicia Santos Savio
* Thomas R Malek